Understanding Anti-Seizure Medications (ASMs) & Child Outcomes

Studies on children born to a parent taking ASMs during pregnancy have shown that for many ASMs, there was little or no difference in the development of babies compared to those born to people who did not take ASMs. The risks of taking certain ASMs during pregnancy are relatively low when compared with other types of medicines or exposure to other substances like thalidomide or alcohol.

ASMs & Pregnancy

To improve your chances for a healthy pregnancy and a healthy baby, ideally you should start planning any adjustments to your ASMs as much as 12 months before trying to become pregnant.

Risk of Major Congenital Malformations
Risk of Adverse ND Outcomes

Visit the American Academy of Neurology's Practice Guidelines for additional information.

Limited to data on major congenital malformations or neurodevelopment
Brivaracetam
Cenobamate
Clobazam
Clonazepam
Diazepam
Eslicarbazepine
Ethosuximide
Epidiolex
Fenfluramine
Gabapentin
Lacosamide
Lorazepam
Perampanel
Pregablin
Rufinamide
Vigabatrin

Common Questions about Anti-Seizure Medications (ASMs) & Child Outcomes

 Consult With Your Doctor

 We understand how having epilepsy can increase your stress about becoming pregnant and delivering a healthy baby. You can rest assured that there is significant research about the safety of various ASMs for you and your baby. Continuing to take your ASM as prescribed throughout pregnancy is an important step in keeping you and your baby safe and healthy.

Download our Pregnancy Planning With Epilepsy - Questions to Ask Your Doctors, and bring a copy to your appointments to help guide your conversations and get the answers you need.

You can also use the Epilepsy Foundation Seizure Diary to track your seizures and share the information with your doctor.

Educating yourself on all that’s involved and making the right decisions before you try to get pregnant can make that journey much easier, less stressful, and safer, for you and your baby.

Reviewed by: EMPC Expert Panel, March 2025